Axa S.A. Has $97.38 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Axa S.A. decreased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.4% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 92,654 shares of the biopharmaceutical company’s stock after selling 8,499 shares during the period. Axa S.A. owned 0.08% of Regeneron Pharmaceuticals worth $97,382,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in REGN. Global Assets Advisory LLC acquired a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $339,594,000. Capital International Investors grew its stake in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the last quarter. First Trust Advisors LP raised its holdings in Regeneron Pharmaceuticals by 115.2% in the 4th quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after acquiring an additional 195,902 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares during the period. Finally, TD Asset Management Inc lifted its position in Regeneron Pharmaceuticals by 162.9% during the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock worth $259,402,000 after acquiring an additional 166,998 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Trading Down 4.2 %

Shares of REGN opened at $1,045.98 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The company has a market cap of $115.31 billion, a price-to-earnings ratio of 30.90, a PEG ratio of 3.72 and a beta of 0.12. The stock has a fifty day moving average price of $1,130.96 and a two-hundred day moving average price of $1,034.01. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The business had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. During the same period in the previous year, the business posted $8.79 earnings per share. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on REGN shares. Wells Fargo & Company reiterated an “overweight” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday. Royal Bank of Canada lowered their target price on Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating on the stock in a report on Tuesday. Morgan Stanley cut their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Leerink Partnrs cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 10th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $1,118.62.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.